Novel solutions for complex pain
At AlgoTx we develop novel solutions to relieve patients with difficult-to-treat « Complex Pain ».
We do so by prioritizing indications that have no proven and approved therapy, and tailoring treatment to the very specific needs of the affected patients.
ATX01 is currently in Phase 2 clinical development in Chemotherapy-Induced Peripheral Neuropathy : The "ACT" study is in progress in the US and Europe. In addition, FDA and the German regulatory authority BfArM approved the initiation of a Phase 2 Proof-of-Concept study of ATX01 in a rare and painful disease, erythromelalgia ; The "EASE" study will start in Q2 2023 in the US and Germany.
ATX01’s topical administration enables the direct blockade of pain messaging in the nerve fibers of the skin, and limits the systemic side-effects potential associated with oral or intravenous drugs.